Latest Information Update: 23 Aug 2016
Price : $50
At a glance
- Originator Glenmark Pharmaceuticals S.A.
- Class Bispecific antibodies; Monoclonal antibodies
- Mechanism of Action CD3 antigen modulators; CD38 antigen modulators; Cytotoxic T lymphocyte modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Multiple myeloma
Most Recent Events
- 08 Jan 2016 Preclinical trials in Multiple myeloma in Switzerland (Parenteral)